At Cromos Pharma our first clinical research project was conducted in breast cancer. Since 2004, we have conducted dozens of trials involving thousands of breast cancer patients. These studies have focused on a range of areas from finding innovative targeted therapies to biosimilar and generic studies aimed at offering wider access to novel treatments. In 2019, our team successfully recruited almost 500 patients (92% of total) for a multi-country breast cancer study in just seven months.
We combine global expertise with in-depth experience and knowledge in Central and Eastern Europe to offer exceptional patient recruitment. In our 16 year history, our team has met or reduced enrollment timelines in 95% of trials conducted. Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program.
We provide the most optimized start-up timelines in our regions. We regularly achieve regulatory approvals in Georgia, within two months of project signing (4 months in Russia, and in less than 5 in Ukraine). Regulatory inspections and site audits also attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
Cromos Pharma is looking forward to taking part in the upcoming DIA Europe conference (15 – 19 March 2021). A highly collaborative event, it’s a great chance to meet with future partners and hear from innovators across the entire life sciences spectrum.
Cromos Pharma is delighted to be participating in MAGI’s Clinical Research vConference (2-5 & 9-12 November). Our CEO Vlad Bogin, MD, FACP will be giving a presentation on the timely topic of Crisis Management (2 November, 2:30 PM-3:30 PM).